文献速递脑血管病外科神经重症

一种新型脑局部尼卡地平递送系统的体外与体内测试:一项临床前研究

In vitro and in vivo testing of a novel local nicardipine delivery system to the brain: a preclinical study.
PubMed 文献 · J Neurosurg · 2019-01-25

本研究在体外用人工脑脊液观察新型尼卡地平制剂NicaPlant的释放动力学,并在C57BL/6小鼠慢性颅窗模型上评估局部耐受性与组织反应。结果显示NicaPlant体外21天持续释放尼卡地平,体内可见动脉扩张且无血管通透性增加、白细胞-内皮细胞相互作用增加或组织结构改变。

要点

  • NicaPlant体外释放呈近线性,第15天约释放80%,第21天完全释放。
  • NicaPlant组动脉直径显著大于对照组(21.6 ± 2.6 µm vs 17.8 ± 1.5 µm,p < 0.01)。
  • 体内未见血管通透性增加、白细胞-内皮细胞相互作用增加或小胶质细胞活化。

核心结论

  • NicaPlant在3周观察期内持续体外释放尼卡地平,体内测试证实其具有血管活性且无毒性,局部应用于蛛网膜下腔是改善患者结局并避免全身副作用的潜在工具。

研究设计与样本

  • 体外采用人工脑脊液进行21天溶出实验以表征NicaPlant的释放动力学。
  • 体内在C57BL/6小鼠制备慢性颅窗,将NicaPlant切片置于暴露的脑血管附近,于植入后即刻及术后第3天和第7天行落射荧光视频显微镜检查。

主要发现

  • 体外尼卡地平释放曲线近似线性,第15天释放约80%,第21天完全释放。
  • NicaPlant组动脉血管直径因血管扩张显著高于对照组(21.6 ± 2.6 µm vs 17.8 ± 1.5 µm,p < 0.01),静脉直径未受影响。
  • 血管扩张对荧光染料对比剂外渗测得的血管通透性无影响,未检测到植入物导致的白细胞-内皮细胞相互作用增加。
  • 组织学分析未显示小胶质细胞活化或积聚,未观察到神经元结构改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The management of patients with aneurysmal subarachnoid hemorrhage (aSAH) remains a highly demanding challenge in critical care medicine. Despite all efforts, the calcium channel antagonist nimodipine remains the only drug approved for improving outcomes after aSAH. However, in its current form of application, it provides less than optimal efficacy and causes dose-limiting hypotension in a substantial number of patients. Here, the authors tested in vitro the release dynamics of a novel formulation of the calcium channel blocker nicardipine and in vivo local tolerance and tissue reaction using a chronic cranial window model in mice. METHODS: To characterize the release kinetics in vitro, dissolution experiments were performed using artificial cerebrospinal fluid over a time period of 21 days. The excipients used in this formulation (NicaPlant) for sustained nicardipine release are a mixture of two completely degradable polymers. A chronic cranial window in C57BL/6 mice was prepared, and NicaPlant slices were placed in proximity to the exposed cerebral vasculature. Epifluorescence video microscopy was performed right after implantation and on days 3 and 7 after surgery. Vessel diameter of the arteries and veins, vessel permeability, vessel configuration, and leukocyte-endothelial cell interaction were quantified by computer-assisted analysis. Immunofluorescence staining was performed to analyze inflammatory reactions and neuronal alterations. RESULTS: In vitro the nicardipine release profile showed an almost linear curve with about 80% release at day 15 and full release at day 21. In vivo epifluorescence video microscopy showed a significantly higher arterial vessel diameter in the NicaPlant group due to vessel dilatation (21.6 ± 2.6 µm vs 17.8 ± 1.5 µm in controls, p < 0.01) confirming vasoactivity of the implant, whereas the venous diameter was not affected. Vessel dilatation did not have any influence on the vessel permeability measured by contrast extravasation of the fluorescent dye in epifluorescence microscopy. Further, an increased leukocyte-endothelial cell interaction due to the implant could not be detected. Histological analysis did not show any microglial activation or accumulation. No structural neuronal changes were observed. CONCLUSIONS: NicaPlant provides continuous in vitro release of nicardipine over a 3-week observation period. In vivo testing confirmed vasoactivity and lack of toxicity. The local application of this novel nicardipine delivery system to the subarachnoid space is a promising tool to improve patient outcomes while avoiding systemic side effects.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Bayerl SH, Ghori A, Nieminen-Kelhä M, et al. In vitro and in vivo testing of a novel local nicardipine delivery system to the brain: a preclinical study. J Neurosurg. 2019. PMID: 30684943. doi:10.3171/2018.9.JNS173085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。